Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis

Nadja Dornhöfer, Suzanne Spong, Kevin Bennewith, Ali Salim, Stephen Klaus, Neeraja Kambham, Carol Wong, Fiona Kaper, Patrick Sutphin, Rendall Nacalumi, Michael Höckel, Quynh Le, Michael Longaker, George Yang, Albert Koong, Amato Giaccia

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth.

Original languageEnglish (US)
Pages (from-to)5816-5827
Number of pages12
JournalCancer Research
Volume66
Issue number11
DOIs
StatePublished - Jun 1 2006

Fingerprint

Connective Tissue Growth Factor
Monoclonal Antibodies
Neoplasm Metastasis
Growth
Neoplasms
Pancreatic Neoplasms
Therapeutics
Agar
Cell Proliferation
Tumor Cell Line
Heterografts
Nude Mice
Suspensions
Adenocarcinoma
Lymph Nodes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dornhöfer, N., Spong, S., Bennewith, K., Salim, A., Klaus, S., Kambham, N., ... Giaccia, A. (2006). Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Research, 66(11), 5816-5827. https://doi.org/10.1158/0008-5472.CAN-06-0081

Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. / Dornhöfer, Nadja; Spong, Suzanne; Bennewith, Kevin; Salim, Ali; Klaus, Stephen; Kambham, Neeraja; Wong, Carol; Kaper, Fiona; Sutphin, Patrick; Nacalumi, Rendall; Höckel, Michael; Le, Quynh; Longaker, Michael; Yang, George; Koong, Albert; Giaccia, Amato.

In: Cancer Research, Vol. 66, No. 11, 01.06.2006, p. 5816-5827.

Research output: Contribution to journalArticle

Dornhöfer, N, Spong, S, Bennewith, K, Salim, A, Klaus, S, Kambham, N, Wong, C, Kaper, F, Sutphin, P, Nacalumi, R, Höckel, M, Le, Q, Longaker, M, Yang, G, Koong, A & Giaccia, A 2006, 'Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis', Cancer Research, vol. 66, no. 11, pp. 5816-5827. https://doi.org/10.1158/0008-5472.CAN-06-0081
Dornhöfer, Nadja ; Spong, Suzanne ; Bennewith, Kevin ; Salim, Ali ; Klaus, Stephen ; Kambham, Neeraja ; Wong, Carol ; Kaper, Fiona ; Sutphin, Patrick ; Nacalumi, Rendall ; Höckel, Michael ; Le, Quynh ; Longaker, Michael ; Yang, George ; Koong, Albert ; Giaccia, Amato. / Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. In: Cancer Research. 2006 ; Vol. 66, No. 11. pp. 5816-5827.
@article{2e410c8575cd4d409b678d033afaa9d6,
title = "Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis",
abstract = "Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth.",
author = "Nadja Dornh{\"o}fer and Suzanne Spong and Kevin Bennewith and Ali Salim and Stephen Klaus and Neeraja Kambham and Carol Wong and Fiona Kaper and Patrick Sutphin and Rendall Nacalumi and Michael H{\"o}ckel and Quynh Le and Michael Longaker and George Yang and Albert Koong and Amato Giaccia",
year = "2006",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-06-0081",
language = "English (US)",
volume = "66",
pages = "5816--5827",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis

AU - Dornhöfer, Nadja

AU - Spong, Suzanne

AU - Bennewith, Kevin

AU - Salim, Ali

AU - Klaus, Stephen

AU - Kambham, Neeraja

AU - Wong, Carol

AU - Kaper, Fiona

AU - Sutphin, Patrick

AU - Nacalumi, Rendall

AU - Höckel, Michael

AU - Le, Quynh

AU - Longaker, Michael

AU - Yang, George

AU - Koong, Albert

AU - Giaccia, Amato

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth.

AB - Pancreatic cancer is highly aggressive and refractory to most existing therapies. Past studies have shown that connective tissue growth factor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer cell lines. To address whether and how CTGF influences tumor growth, we generated pancreatic tumor cell lines that overexpress different levels of human CTGF. The effect of CTGF overexpression on cell proliferation was measured in vitro in monolayer culture, suspension culture, or soft agar, and in vivo in tumor xenografts. Although there was no effect of CTGF expression on proliferation in two-dimensional cultures, anchorage-independent growth (AIG) was enhanced. The capacity of CTGF to enhance AIG in vitro was linked to enhanced pancreatic tumor growth in vivo when these cells were implanted s.c. in nude mice. Administration of a neutralizing CTGF-specific monoclonal antibody, FG-3019, had no effect on monolayer cell proliferation, but blocked AIG in soft agar. Consistent with this observation, anti-CTGF treatment of mice bearing established CTGF-expressing tumors abrogated CTGF-dependent tumor growth and inhibited lymph node metastases without any toxicity observed in normal tissue. Together, these studies implicate CTGF as a new target in pancreatic cancer and suggest that inhibition of CTGF with a human monoclonal antibody may control primary and metastatic tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=33745247375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745247375&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-0081

DO - 10.1158/0008-5472.CAN-06-0081

M3 - Article

C2 - 16740721

AN - SCOPUS:33745247375

VL - 66

SP - 5816

EP - 5827

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -